Drew Kennedy

Drew Kennedy is an accomplished biotechnology professional with extensive experience in technology development and research. Currently serving as Director of Technology Development at Guardant Health since April 2020, Drew has held several key positions within the company, including Associate Director and Manager of Technology Development, focusing on novel liquid biopsy assay development. Prior experience includes roles as Senior Scientist at Illumina, Lead Scientist at Roswell Biotechnologies, and Senior Scientist at Agilent Technologies, where Drew contributed to the development of CRISPR-based genome engineering tools. Educational qualifications comprise a PhD in Bioengineering from Stanford University, an MSc in Bioengineering from Caltech, and a BEng in Chemical Engineering and Biosciences from McMaster University.